Total Payments
$1.7M
2024 Payments
$191,306
Companies
23
Transactions
1,663
Medicare Patients
2,495
Medicare Billing
$576,785
Payment Breakdown by Category
Other$1.2M (72.4%)
Consulting$263,180 (15.3%)
Travel$120,228 (7.0%)
Research$48,095 (2.8%)
Food & Beverage$37,020 (2.2%)
Education$6,027 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 460 | 60.5% |
| Consulting Fee | $263,180 | 92 | 15.3% |
| Honoraria | $204,071 | 95 | 11.9% |
| Travel and Lodging | $120,228 | 449 | 7.0% |
| Unspecified | $48,095 | 14 | 2.8% |
| Food and Beverage | $37,020 | 546 | 2.2% |
| Education | $6,027 | 7 | 0.4% |
Payments by Type
General
$1.7M
1,649 transactions
Research
$48,095
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $680,863 | 592 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $246,962 | 203 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $182,697 | 139 | $0 (2024) |
| Kyowa Kirin, Inc. | $153,278 | 126 | $0 (2024) |
| Acorda Therapeutics, Inc | $111,868 | 98 | $0 (2024) |
| UCB, Inc. | $87,112 | 152 | $0 (2019) |
| US WorldMeds, LLC | $61,387 | 99 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $59,857 | 71 | $0 (2018) |
| Adamas Pharmaceuticals, Inc. | $53,535 | 60 | $0 (2021) |
| Lundbeck LLC | $29,454 | 46 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $191,306 | 161 | Neurocrine Biosciences, Inc. ($76,021) |
| 2023 | $260,925 | 224 | ACADIA Pharmaceuticals Inc ($99,016) |
| 2022 | $195,231 | 167 | ACADIA Pharmaceuticals Inc ($78,100) |
| 2021 | $185,299 | 136 | ACADIA Pharmaceuticals Inc ($71,934) |
| 2020 | $97,887 | 81 | ACADIA Pharmaceuticals Inc ($30,355) |
| 2019 | $284,169 | 312 | ACADIA Pharmaceuticals Inc ($98,770) |
| 2018 | $246,458 | 321 | ACADIA Pharmaceuticals Inc ($83,062) |
| 2017 | $257,295 | 261 | ACADIA Pharmaceuticals Inc ($180,199) |
All Payment Transactions
1,663 individual payment records from CMS Open Payments — Page 1 of 67
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Honoraria | Cash or cash equivalent | $3,015.00 | General |
| Category: NEUROLOGY | ||||||
| 12/23/2024 | Amneal Pharmaceuticals LLC | — | Honoraria | Cash or cash equivalent | $2,412.00 | General |
| 12/18/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $3,015.00 | General |
| Category: NEUROLOGY | ||||||
| 12/18/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $871.59 | General |
| Category: NEUROLOGY | ||||||
| 12/17/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $109.54 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Travel and Lodging | In-kind items and services | $18.76 | General |
| Category: NEUROLOGY | ||||||
| 12/13/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $927.00 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $6,625.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,110.50 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $376.50 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $38.89 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Amneal Pharmaceuticals LLC | — | Food and Beverage | In-kind items and services | $12.88 | General |
| 12/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $3,919.50 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $108.77 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,110.50 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $1,009.48 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,710.00 | General |
| Category: Neuropsychiatry | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $119.98 | General |
| Category: Neuropsychiatry | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $40.20 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,710.00 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $944.81 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $173.11 | General |
| Category: Neuropsychiatry | ||||||
| 11/07/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $25,211 | 1 |
| A MULTICENTER, OPEN LABEL, TWO-ARM STUDY TO EVALUATE THE IMPACT OF USING WEARABLE DEVICES IN ADDITION TO STANDARD CLINICAL PRACTICE ON PARKINSON'S SUBJECT SYMPTOMS MANAGEMENT - PHASE 4 | UCB SA | $10,928 | 2 |
| ACP-103-048 | ACADIA Pharmaceuticals Inc | $4,000 | 1 |
| Patient and physician perceptions of disease management in Parkinsons disease - Results from a US-based multicenter survey | UCB, Inc. | $2,300 | 1 |
| A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | Amneal Pharmaceuticals LLC | $2,000 | 1 |
| TARGET-PD | Global Kinetics USA Corporation | $2,000 | 1 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE | H. Lundbeck A S | $1,495 | 1 |
| A STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH PARKINSON'S DISEASE PSYCHOSIS | Sunovion Pharmaceuticals Inc. | $161.22 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 666 | 1,134 | $352,616 | $152,514 |
| 2022 | 3 | 639 | 1,171 | $382,067 | $164,412 |
| 2021 | 3 | 601 | 1,105 | $352,284 | $150,547 |
| 2020 | 6 | 589 | 1,027 | $272,487 | $109,311 |
Total Patients
2,495
Total Services
4,437
Medicare Billing
$576,785
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 212 | 465 | $106,462 | $70,333 | 66.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 158 | 276 | $133,598 | $33,444 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 90 | 90 | $25,553 | $16,945 | 66.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 157 | $25,726 | $16,692 | 64.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 102 | $33,864 | $7,959 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $27,412 | $7,141 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 199 | 481 | $113,590 | $74,118 | 65.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 150 | 306 | $154,836 | $39,304 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 97 | 97 | $28,325 | $19,026 | 67.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 152 | $25,298 | $16,583 | 65.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 47 | 47 | $30,362 | $7,936 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 56 | 88 | $29,656 | $7,445 | 25.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 160 | 359 | $84,646 | $56,173 | 66.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 145 | 294 | $144,060 | $40,060 | 27.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 213 | $36,253 | $22,352 | 61.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 72 | 72 | $21,096 | $13,895 | 65.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 129 | $42,441 | $11,553 | 27.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $23,788 | $6,513 | 27.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 159 | 369 | $69,711 | $44,838 | 64.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 145 | 284 | $112,434 | $27,433 | 24.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 63 | 63 | $17,065 | $11,364 | 66.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 68 | 113 | $15,711 | $10,097 | 64.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 61 | 101 | $28,610 | $6,461 | 22.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 40 | 40 | $24,280 | $5,676 | 23.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 21 | 21 | $1,795 | $1,357 | 75.6% |
About Dr. David Kreitzman, M.D
Dr. David Kreitzman, M.D is a Neurology healthcare provider based in Commack, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1427056605.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kreitzman, M.D has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $191,306 received in 2024. These payments were reported across 1,663 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Kreitzman has provided services to 2,495 Medicare beneficiaries, totaling 4,437 services with total Medicare billing of $576,785. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Commack, NY
- Active Since 07/12/2005
- Last Updated 04/02/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427056605
Products in Payments
- NUPLAZID (Drug) $679,063
- INGREZZA (Drug) $185,160
- RYTARY (Drug) $136,852
- INBRIJA (Drug) $111,691
- NOURIANZ (Drug) $96,930
- Neupro (Drug) $87,112
- Nourianz (Drug) $56,348
- AUSTEDO (Drug) $55,368
- GOCOVRI (Drug) $54,035
- ONGENTYS (Drug) $52,671
- APOKYN (Drug) $34,093
- NORTHERA (Drug) $30,949
- Xadago (Drug) $30,599
- CREXONT (Drug) $25,468
- Ongentys (Drug) $24,924
- KYNMOBI (Drug) $7,055
- SD809-HD (Drug) $3,927
- CARBIDOPA AND LEVODOPA (Drug) $2,000
- PERSONAL KINETIGRAPH (PKG) (Device) $2,000
- DISEASE EDUCATION (Drug) $1,800
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Commack
Shakira Shanker, M.d, M.D
Neurology — Payments: $49,057
Neurology $49,057
Tal Mednick, Md, MD
Neurology — Payments: $4,990
Neurology $4,990
Dr. Christopher Bondoc, Md, MD
Neurology — Payments: $4,084
Neurology $4,084
Dr. Daniel Scutaro, D.c, D.C
Neurology
Neurology
Dr. Lori Hochman, Pt, PT
Neurology
Neurology